Download Namzaric

Special points of interest

th

December 24 2014 FDA approved the release of Namzaric

Used for the treatment of: Moderate to severe dementia of the

Alzheimer's type in patients stabilized on memantine hydrochloride
and donepezil hydrochloride.
Dosage: Once daily oral capsule.

Marketing Information from Manufacturer:


"Namzaric (nam-ZAIR-ick) combines, in one capsule, two
complementary therapeutic agents which are often co-prescribed as
approximately 70% of Namenda XR patients. Both Namenda XR and
donepezil have proven efficacy and safety, for the treatment of
moderate to severe Alzheimer's disease. Additionally, data has
shown that combination therapy demonstrated greater
improvement in cognition and global function verses one of the
drugs alone," said David Nicholson, Actavis Senior Vice President,
Global Brands R&D.
Benefits and Concerns of the Drug: For patients who are
stabilized on these two complimentary therapeutic agents,
Namzaric offers and predictable dosing in an easy to use dosage
form. But, fixed dosage forms generally limit the ability to tailor the
patient dosing of each ingredient around their specific needs. And,
patients that may take more medication than required may over
dose which is problematic with extended release capsules. Both of
these concerns are real concerns with Alzheimer’s patients.
Coverage Recommendations: These recommendations are
available to IPC/EvergreenRx clients from their Account Manager or
Clinical Pharmacist.
Please contact us with any questions or comments

B r an d Na m e
Nam z ar ic (n am -Z AIR - ic k )

Nam z ar ic , f or m er l y
kn own as M D X -8 70 4 , is
a on ce -d a il y or a l

cap su le
Gen er ic n am e
d on ep ez i l & m em an ti n e
T 636.614.1344
www.ipc-inc.com
A Brown & Brown company